The South African Pharmacy Council (SAPC), the Health Professions Council of South Africa (HPCSA) and the South African Health Products Regulatory Authority (SAHPRA) said in a joint statement that the affected products in the recall include semaglutide, tirzepatide and semaglutide/tirzepatide combinations that are mixed together by iDexis
Peptide nasal sprays offer fast absorption through the nasal mucosa, quickly entering the bloodstream, bypassing the digestive system and potentially leading to faster results
The most commonly observed side effects include mild injection-site irritation and nausea, which subside within the first week or two, especially at lower doses
[4] Some preclinical and early clinical research has explored its potential in contexts involving cerebral ischemia, though much of this evidence is preliminary or derived from Eastern European clinical populations and should be interpreted cautiously
When your body has sufficient collagen, your skin looks smoother and more resilient
